World Health Organization Issues Warning Over Critical Lack of Weight-Loss Medications
Under one in 10 individuals eligible to benefit from obesity jabs like Wegovy are able to get them, warns the WHO as it publishes its inaugural guidance on the drugs.
Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for increased and just access to these injectable treatments.
According to projections, more than two billion will be living with obesity by 2030 if no action is taken.
"The new guidelines recognises that obesity is a lifelong illness that can be managed with comprehensive and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are key barriers to universal access to the jabs that can assist patients in reducing considerable body mass, explains the agency.
Skinny Jab Supply Crisis
Even in the present most optimistic case, the supply of such drugs could only cover around 100 million people – less than 10% of eligible patients, as stated by the WHO.
The advice encourages governments and firms to widen access, by strategies such as voluntary licensing.
The intellectual property rights on the active ingredient – the main ingredient of the drug Wegovy – is set to lapse in multiple countries in 2026.
How Weight-Loss Injections Operate
GLP-1 drugs replicate a biological compound to delay gastric emptying, curb appetite and boost feelings of fullness so users eat less.
Individuals usually begin shedding pounds after several weeks of commencing the weekly injections.
Evidence points to users may see weight return a year later of discontinuing the medication, because their normal hunger return.
To be overweight or obese elevates your likelihood for developing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight concerns people in every country and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
